Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: Results from a randomized controlled study

Inflammatory Bowel Diseases

Volumn 13, Issue 9, 2007, Pages 1115-1120

  Yokoyama, Hiroshi ^a   Takagi, Sho ^d   Kuriyama, Shinichi ^a   Takahashi, Shuichiro ^a   Takahashi, Hiroki ^b   Iwabuchi, Masahiro ^b   Takahashi, Seiichi ^a   Kinouchi, Yoshitaka ^a   Hiwatashi, Nobuo ^c   Tsuji, Ichiro ^a   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SENDAI CITY MEDICAL CENTER   (Japan)

^c Iwaki Kyoritsu General Hospital   (Japan)

^d Graduate School of Medicine ^*

Author keywords

5 ASA; Enema; Maintenance therapy; Randomized controlled trial; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; ENEMA; MESALAZINE; PREDNISOLONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAINTENANCE THERAPY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REMISSION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; ENEMA; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548603473     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20158     Document Type: Article

References (23)

1. Biddle WL, Greenberger NJ, Swan T. et al. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology. 1988;94:1075-1079.
2. Andreoli A, Spinella S, Levenstein S. et al. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis. Ital J Gastroenterol. 1994;26:121-125.
3. Mantzaris GJ, Hatzis A, Petraki K, et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proct sigmoiditis. Dis Colon Rectum. 1994;37:58-62.
4. D'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double blind study. Am J Gastroenterol. 1997;92:1143-1147.
5. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2003;3:CD000543.
6. Hanauer SB, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis. Am J Gastroenterol. 1993;88:1188-1197.
7. Miner P, Hanauer SB, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci. 1995;40:296-304.
8. Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol. 2000;95:1628-1636.
9. Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95:1263-1276.
10. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005;54:960-965.
11. Safdi MA, Demicco MP, Sninsky CA, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867-1871.
12. Campieri M, Gionchetti P, Belluzzi A, et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut. 1991;32:929-931.
13. Hanauer S. Dose-ranging study of mesalamine (Pentasa) in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. Inflamm Bowel Dis. 1998;4:79-83.
14. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000;23:429-448.
15. Jani N, Regueiro MD. Medical therapy for ulcerative colitis. Gastroenterol Clin North Am. 2002;31:147-166.
16. Yang Y-X, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol. 2002;97:803-823.
17. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of controlled trial. Am J Gastroenterol. 1993;88:1188-1197.
18. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutical trial. BMJ. 1955;2:1041-1048.
19. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. BMJ. 1964;5375:89-92.
20. Truelove SC, Richards WD. Biopsy studies in ulcerative colitis. BMJ. 1956;1:1315-1318.
21. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. BMJ. 1989;298:82-86.
22. Vecchi M, Meucci G, Gionchetti P, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther. 2001;15:251-256.
23. Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut. 2001;49:783-789.